News & Updates

Delays in endoscopies due to the coronavirus disease 2019 (COVID-19) pandemic does not seem to worsen clinical outcomes in patients with inflammatory bowel diseases (IBD), though healthcare utilization patterns appear to be affected, according to a study reported at the recently concluded 2022 Crohn’s & Colitis Congress (CCC 2022).

East Asia topped the world’s incidence and mortality of lung cancer in 2020, according to a global study conducted by the Chinese University of Hong Kong (CUHK) and the Association of Pacific Rim Universities (APRU).

In patients with inflammatory bowel disease (IBD), erectile and sexual dysfunction (SD) are significantly associated with psychological factors, but IBD severity appears to have no impact on such conditions, suggests a recent study. Likewise, the type of medication used to treat the underlying disease has no influence on SD development.

Persons living with HIV (PLWH) often switch from first-line antiretroviral therapies (ART) of non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PI) to second-line integrase strand transfer inhibitors (INSTI), a recent Japan study has found. PLWHs tend to stay on INSTIs for a long time thereafter.

In Gleason grade group (GGG) 3 prostate cancer patients with a single intermediate-risk positive biopsy core, risk downgrading appears to be more likely than upgrading, reports a new study.